Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
South Korean, Celltrion group is a global leader for biologic medicine and is a pioneer in the approval of biosimilar profile in Europe, US and Brazil. The…
A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.
Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.
Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.